Kane Biotech (CVE:KNE) Stock Price Up 28.6% – Time to Buy?

by · The Markets Daily

Shares of Kane Biotech Inc. (CVE:KNE – Get Free Report) rose 28.6% during mid-day trading on Saturday . The company traded as high as C$0.05 and last traded at C$0.05. Approximately 1,505,028 shares changed hands during mid-day trading, an increase of 380% from the average daily volume of 313,629 shares. The stock had previously closed at C$0.04.

Kane Biotech Price Performance

The stock has a market cap of C$7.53 million, a price-to-earnings ratio of -0.56 and a beta of 0.60. The company has a quick ratio of 0.39, a current ratio of 0.80 and a debt-to-equity ratio of -331.42. The company’s 50-day moving average is C$0.04 and its 200-day moving average is C$0.04.

Kane Biotech Company Profile

(Get Free Report)

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.

See Also